A panelist discusses how recent advances in transurethral resection of bladder tumor (TURBT) include enhanced visualization techniques like fluorescence-guided surgery and narrow-band imaging to ...

Nuclear speckles in ccRCC exist in two states, Signature I and II, affecting tumor behavior and patient outcomes. Signature I is linked to later-stage tumors and poorer outcomes, while Signature II is ...

TLX250-CDx aims to address unmet needs in ccRCC imaging, with a potential U.S. commercial launch in 2025. The FDA's initial concerns were related to sterility assurance, not the agent's safety or ...

"I think that it's so important right now to really, really stand as your own brand and really, really have a cultivated patient population that you're after," says Gia Ching. In this video, Amy M.

Erdafitinib received full FDA approval for FGFR3-positive urothelial carcinoma, demonstrating improved overall survival in the phase 3 THOR trial. Cefepime ...

“There's state advocacy work groups and other public policy work groups where folks can remain involved and keep pushing to improve the delivery of health care,” says Juan J. Andino, MD, MBA. In this ...

"We are now in the golden era of BPH/BPO for both diagnostics and therapeutics," says Wayne Kuang, MD. In this video, Wayne Kuang, MD, shares his thoughts on what advances in benign prostatic ...

Quiz: What CUA guidelines say about genomic profiling of tumors in prostate cancer ...

“This is another therapeutic that adds to UroGen [profile] as a potential treatment that could be used to preserve kidneys while treating low grade upper tract urothelial carcinoma going forward,” ...

BCG-unresponsive NMIBC is defined by persistent or recurrent high-grade tumors or carcinoma in situ after adequate BCG therapy. This condition requires alternative therapeutic strategies or radical ...

“Women not only tend to present with more aggressive disease, but they also have a higher probability of having what we call variant histology, so non-urothelial carcinoma,” says Ava Saidian, MD. In ...

Lenvatinib/pembrolizumab and nivolumab/cabozantinib show improved survival and response rates in advanced renal cell carcinoma. Machine learning and surgical algorithms are advancing personalized ...